Publication | Closed Access

Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study

Esophageal CancerGastrointestinal OncologyMedicineClinical TrialsPathologyMolecular OncologyCancer TreatmentSecond-line TherapyOncologyRadiation OncologyCancer ResearchCamrelizumab Versus InvestigatorHealth Sciences